Summary
Acute myeloid leukemias (AML) are aggressive blood cancers with poor overall prognosis. The main intervention line is high-dose chemotherapy, often associated with resistance, relapse and long-term side effects. Although predominantly considered as genetic diseases of the hematopoietic system, AML also affect the bone marrow (BM) microenvironment, which contributes to disease pathogenesis. Particularly, we have revealed a thorough remodeling of the vascular tree, with endothelial cells (ECs) displaying dismantled junctions and an embryonic-like molecular signature.
Our research hypothesis is that this embryonic-like ECs (E-ECs)– displaying a high grade of plasticity – are progressively enriched during AML progression and foster a leukemia-reinforcing environment. Thus, this proposal aims at (1) deciphering the nature of enriched E-ECs in AML pathogenesis and (2) identifying effective strategies to target them to improve therapeutic response.
To this end, we will combine in vivo lineage tracing and OMIC studies in consolidated transplantable models of AML and patient-derived samples to decipher the molecular and clonal dynamics of BM ECs as well as their phenotypic plasticity toward regained Endothelial-to-Hematopoietic and Endothelial-to-Mesenchymal transition potential. We will next explore novel therapeutic avenues by targeting microenvironmental plasticity in AML via candidate genes associated with the aforementioned phenotypes in vivo with engineered CRISPR-nanobodies. Finally, this knowledge will be translated to the human system via pre-clinical validation of putative targets in a state-of-the-art human vascularized BM-on-chip platform.
In conclusion, this research proposal will uncover essential molecular mechanisms regulating stem cell niche dynamics in normal and pathological conditions, provide a thorough understanding of the molecular and cellular plasticity of BM ECs and will result in innovative strategies to ameliorate AML clinical treatments.
Our research hypothesis is that this embryonic-like ECs (E-ECs)– displaying a high grade of plasticity – are progressively enriched during AML progression and foster a leukemia-reinforcing environment. Thus, this proposal aims at (1) deciphering the nature of enriched E-ECs in AML pathogenesis and (2) identifying effective strategies to target them to improve therapeutic response.
To this end, we will combine in vivo lineage tracing and OMIC studies in consolidated transplantable models of AML and patient-derived samples to decipher the molecular and clonal dynamics of BM ECs as well as their phenotypic plasticity toward regained Endothelial-to-Hematopoietic and Endothelial-to-Mesenchymal transition potential. We will next explore novel therapeutic avenues by targeting microenvironmental plasticity in AML via candidate genes associated with the aforementioned phenotypes in vivo with engineered CRISPR-nanobodies. Finally, this knowledge will be translated to the human system via pre-clinical validation of putative targets in a state-of-the-art human vascularized BM-on-chip platform.
In conclusion, this research proposal will uncover essential molecular mechanisms regulating stem cell niche dynamics in normal and pathological conditions, provide a thorough understanding of the molecular and cellular plasticity of BM ECs and will result in innovative strategies to ameliorate AML clinical treatments.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101116663 |
| Start date: | 01-07-2024 |
| End date: | 30-06-2029 |
| Total budget - Public funding: | 1 499 000,00 Euro - 1 499 000,00 Euro |
Cordis data
Original description
Acute myeloid leukemias (AML) are aggressive blood cancers with poor overall prognosis. The main intervention line is high-dose chemotherapy, often associated with resistance, relapse and long-term side effects. Although predominantly considered as genetic diseases of the hematopoietic system, AML also affect the bone marrow (BM) microenvironment, which contributes to disease pathogenesis. Particularly, we have revealed a thorough remodeling of the vascular tree, with endothelial cells (ECs) displaying dismantled junctions and an embryonic-like molecular signature.Our research hypothesis is that this embryonic-like ECs (E-ECs)– displaying a high grade of plasticity – are progressively enriched during AML progression and foster a leukemia-reinforcing environment. Thus, this proposal aims at (1) deciphering the nature of enriched E-ECs in AML pathogenesis and (2) identifying effective strategies to target them to improve therapeutic response.
To this end, we will combine in vivo lineage tracing and OMIC studies in consolidated transplantable models of AML and patient-derived samples to decipher the molecular and clonal dynamics of BM ECs as well as their phenotypic plasticity toward regained Endothelial-to-Hematopoietic and Endothelial-to-Mesenchymal transition potential. We will next explore novel therapeutic avenues by targeting microenvironmental plasticity in AML via candidate genes associated with the aforementioned phenotypes in vivo with engineered CRISPR-nanobodies. Finally, this knowledge will be translated to the human system via pre-clinical validation of putative targets in a state-of-the-art human vascularized BM-on-chip platform.
In conclusion, this research proposal will uncover essential molecular mechanisms regulating stem cell niche dynamics in normal and pathological conditions, provide a thorough understanding of the molecular and cellular plasticity of BM ECs and will result in innovative strategies to ameliorate AML clinical treatments.
Status
SIGNEDCall topic
ERC-2023-STGUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
Search
